The phase III malaria vaccine, R21, funded by Wellcome, shows potential for a transformative impact on malaria in children. Health economist Roger Bate emphasizes the need for vigilance in using bed nets and treating fevers. Despite stagnated efforts to control malaria, the R21/Matrix-M vaccine raises hopes, but successful implementation remains to be seen. Gavi highlights the potential of the vaccines in ending malaria but acknowledges the challenges outlined by The Lancet.
The world now has two safe and effective vaccines working alongside other interventions to protect communities and #endmalaria. The vaccines raise hope for malaria control but, as outlined by @TheLancet, there are challenges: https://t.co/NoASlebv1E
Despite ambitions to reduce burden, efforts to control malaria have stagnated. The RTS,S/AS01 & R21/Matrix-M vaccines raise fresh hopes for malaria control; how successfully countries will implement vaccine roll-out remains to be seen. Our Editorial: https://t.co/fE0O2PS3qW https://t.co/eKZqvKlAlg
For @Quillette, @RogerBate3 reports on the new malaria vaccine. It's not a wonder drug and will have to managed correctly, but it will significantly help. https://t.co/CT2KhSmsAd
Health economist @RogerBate3 writes that the new vaccine will help in the fight against malaria, but only if parents continue to be vigilant about the use of bed nets & continue to treat their children's fevers as possible cases of the disease https://t.co/AvTkgUsegs
Will the New Vaccine Help Eradicate Malaria? | @RogerBate3 https://t.co/2J8DSJlblr
Building on early stage studies funded by Wellcome, the results from this recent phase III #malaria vaccine, R21, holds huge potential for a transformative impact on malaria in children. Learn more from @UniofOxford ⤵️ https://t.co/KYAuoDUzRy